# Evaluation of ADG20 for the Prevention of COVID-19

> **NCT04859517** · PHASE2,PHASE3 · TERMINATED · sponsor: **Invivyd, Inc.** · enrollment: 2582 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** ADG20
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04859517
- **Lead sponsor:** Invivyd, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-27
- **Primary completion:** 2022-11-04
- **Final completion:** 2022-11-04
- **Target enrollment:** 2582 (ACTUAL)
- **Why stopped:** All primary efficacy data has been collected and analyzed. Based on the safety data gathered to date, it has been determined that continued participation by study subjects would not yield any additional beneficial safety information.
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04859517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04859517, "Evaluation of ADG20 for the Prevention of COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04859517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*